Vertex
Pharmaceuticals VRTX today announced 12-week
results from an ongoing Phase 2b study of VX-509, an investigational
oral, selective Janus kinase 3 (JAK3) inhibitor, dosed once or twice
daily in people with active rheumatoid arthritis (RA) taking
methotrexate. The study met its primary endpoints of both the proportion
of people who achieved at least a 20 percent improvement in signs and
symptoms of RA, as measured by the ACR improvement criteria (ACR20), and
the change from baseline in Disease Activity Score for 28 joints
(DAS28). All doses of VX-509 showed statistically significant ACR20 and
ACR50 responses versus placebo and statistically significant improvement
from baseline in DAS28 versus placebo. The three highest dose groups
showed
See full press release
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in